Core Viewpoint - The PayPal class action lawsuit alleges that the company and certain executives misled investors regarding the company's revenue outlook and growth potential during the Class Period from February 25, 2025, to February 2, 2026 [1][3]. Group 1: Lawsuit Details - The lawsuit, titled Goodman v. PayPal Holdings, Inc., claims violations of the Securities Exchange Act of 1934 by PayPal and its executives [1]. - The class action seeks to represent purchasers or acquirers of PayPal common stock during the specified Class Period [1][2]. - Allegations include creating a false impression of reliable revenue projections and downplaying risks associated with seasonality and macroeconomic factors [3]. Group 2: Financial Performance - On February 3, 2026, PayPal announced disappointing financial results for Q4 and the full fiscal year 2025, which included a decline in Branded Checkout performance and the withdrawal of previously set 2027 financial targets [4]. - The company attributed its poor performance and lowered guidance to macroeconomic factors, competition, and operational issues across all regions [4]. - Following the announcement, PayPal's stock price reportedly fell by more than 20% [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased PayPal common stock during the Class Period to seek appointment as lead plaintiff in the lawsuit [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering a total of $8.4 billion for investors over the past five years, significantly more than any other law firm [6].

Core Viewpoint - The Enphase Energy class action lawsuit alleges that the company and its executives made misleading statements regarding their financial and operational capabilities, leading to significant stock price declines following the disclosure of poor financial results [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of Enphase Energy securities from April 22, 2025, to October 28, 2025 [1]. - The lawsuit is titled Tripathi v. Enphase Energy, Inc., and is filed in the Northern District of California [1]. - Allegations include overstating the company's ability to manage channel inventory and mitigate the impact of the termination of the Residential Clean Energy Credit [3]. Group 2: Financial Impact - On October 28, 2025, Enphase Energy reported third-quarter financial results, indicating that elevated channel inventory would lead to lower battery storage shipments in the fourth quarter of 2025 [4]. - The expiration of the 25D Credit is expected to negatively impact revenues for the first quarter of 2026 [4]. - Following the announcement, Enphase Energy's stock price fell by more than 15% [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Enphase Energy securities during the class period to seek appointment as lead plaintiff [5]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [5]. - Participation as a lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [6]. - The firm has ranked 1 in securities class action recoveries for four out of the last five years, totaling $8.4 billion in recoveries during that period [6].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving ImmunityBio, Inc. and its officers or directors [1]. Group 1: Company Overview - ImmunityBio, Inc. is listed on NASDAQ under the ticker IBRX [1]. - The company recently announced updated Phase 2 clinical results for a chemotherapy-free combination immunotherapy regimen targeting second-line recurrent or progressive glioblastoma [3]. Group 2: Recent Developments - On January 23, 2026, ImmunityBio reported that the median overall survival, a primary endpoint for its clinical trial, has not yet been reached [3]. - Following the announcement of the clinical results, ImmunityBio's stock price decreased by $0.89 per share, representing a 12.13% decline, closing at $6.45 per share [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by PennyMac Financial Services, Inc. and its officers or directors following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On January 29, 2026, PennyMac reported disappointing financial results for Q4 2025, indicating challenges in capitalizing on refinance opportunities due to increased competition in the origination market [3]. - Following the earnings report, PennyMac's stock price fell by $49.78 per share, or 33.25%, closing at $99.92 per share on January 30, 2026 [4]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of PennyMac investors, suggesting potential securities fraud or other unlawful practices by the company and its leadership [1].

Core Viewpoint - A class action lawsuit has been filed against PayPal Holdings, Inc. for securities fraud, following a significant drop in stock price after a leadership change and disappointing earnings report [1]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased PayPal common stock between February 25, 2025, and February 2, 2026 [1]. - Investors have until April 20, 2026, to file a lead plaintiff motion [1]. - The lawsuit alleges that PayPal made materially false and misleading statements regarding its business operations and prospects during the class period [1]. Group 2: Company Performance - On February 3, 2026, PayPal announced the immediate replacement of CEO Alex Chriss, citing that the pace of change and execution did not meet the Board's expectations [1]. - The company's fourth quarter and full year 2025 earnings report revealed a net revenue increase of only 3% on a currency-neutral basis [1]. - Following the announcement, PayPal's stock price fell by $10.63, or 20.3%, closing at $41.70 per share [1]. Group 3: Allegations Against Defendants - The complaint claims that PayPal overstated its ability to execute on business initiatives and failed to effectively address competition concerns [1]. - It is alleged that the positive statements made by the defendants regarding the company's business were materially misleading and lacked a reasonable basis [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ashford Hospitality Trust, Inc. and its officers or directors [1]. Group 1: Company Actions - On January 13, 2026, Ashford announced the extension of its Highland mortgage loan secured by 18 hotels and suspended preferred dividends to maintain liquidity while evaluating strategic alternatives [3]. - Following the announcement, Ashford's stock price decreased by $0.35 per share, or 8.1%, closing at $3.97 per share on the same day [3]. Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Disc Medicine, Inc. and its officers or directors [1] Group 1: Company Overview - Disc Medicine, Inc. is publicly traded on NASDAQ under the ticker symbol IRON [1] - The company is currently facing scrutiny due to a delay in the review timeline of a drug under development, which has raised safety and efficacy concerns flagged by the U.S. Food and Drug Administration [3] Group 2: Stock Performance - Following the news of the FDA's concerns, Disc's stock price experienced a decline of $6.04 per share, representing a 7.84% drop, closing at $71.04 per share on January 15, 2026 [3] Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members in the past [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Pinterest, Inc. and its officers or directors, following a significant restructuring announcement by the company [1][3]. Group 1: Company Actions - On January 27, 2026, Pinterest announced a global restructuring plan that includes a workforce reduction affecting less than 15% of its employees and a reduction in office space [3]. - The company anticipates incurring pre-tax restructuring charges of approximately $35 million to $45 million, primarily in cash-related expenditures [3]. - The restructuring aims to support transformation initiatives focused on reallocating resources to AI roles, prioritizing AI-powered products, and accelerating changes in sales and marketing strategies [3]. Group 2: Market Reaction - Following the announcement of the restructuring plan, Pinterest's stock price fell by $2.49 per share, or 9.61%, closing at $23.41 per share on January 27, 2026 [3].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ: PYPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PayPal and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On February 3 ...

Core Viewpoint - A class action lawsuit has been filed against PomDoctor Ltd. for alleged securities fraud and unlawful business practices, with a significant drop in share price following a promotional scheme [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by investors who believe PomDoctor and its officers engaged in securities fraud [2]. - Investors have until April 6, 2026, to request to be appointed as Lead Plaintiff if they purchased PomDoctor securities during the Class Period [2]. Group 2: Share Price Movement - PomDoctor's share price increased from $4.00 at its IPO to an all-time high of $6.09 before crashing by approximately 91% to $0.50 on December 10, 2025 [4][5]. - The price surge occurred without any fundamental news justifying the increase, leading to investigations into the company's practices [4]. Group 3: Allegations of Fraud - Investigations revealed that PomDoctor allegedly used social media for a "pump and dump" scheme, misleading investors through impersonators posing as financial advisors [4]. - The scheme involved creating a buying frenzy among retail investors with sensational but unfounded claims [4].